Recombinant Human CD24 Protein，His

CD24 is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein that plays a significant role in cell adhesion, immune response modulation, and tumor progression. It is expressed in various cell types, including hematopoietic cells, and has been closely associated with cancer biology, particularly in facilitating tumor metastasis and immune evasion. Research has demonstrated that CD24 interacts with several ligands and signaling pathways, influencing cellular behavior and fate. The interest in CD24 as a therapeutic target has surged, given its potential to serve as a biomarker for cancer diagnosis and prognosis. Additionally, recombinant CD24 proteins have been developed for functional studies and preclinical applications, allowing researchers to elucidate its mechanisms in disease processes and explore avenues for targeted therapies. As such, studying recombinant CD24 not only enhances our understanding of its biological functions but also opens new possibilities for innovative cancer treatment strategies. Through the production and characterization of CD24 recombinant proteins, scientists aim to dissect its role in immune modulation, identify potential interactions with other tumor-associated factors, and develop novel approaches that could mitigate CD24's contribution to tumorigenesis and metastasis. This research is pivotal for advancing our knowledge of oncological processes and improving personalized medicine approaches in cancer therapy.